Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

被引：0

作者：

Tchao, Nadia ^{[1
]}

Amouzadeh, Hamid ^{[2
]}

Sarkar, Nandita ^{[1
]}

Chow, Vincent ^{[2
]}

Hu, Xuguang ^{[1
]}

Kroenke, Mark ^{[2
]}

Wang, Hui ^{[2
]}

Zhang, Rong ^{[2
]}

Gorski, Kevin ^{[1
]}

Furie, Richard ^{[3
]}

Kivitz, Alan ^{[4
]}

Cohen, Stanley ^{[5
]}

机构：

[1] Amgen Inc, San Francisco, CA USA

[2] Amgen Inc, Thousand Oaks, CA USA

[3] Zucker Sch Med Hofstra Northwell, Great Neck, NY USA

[4] Altoona Ctr Clin Res, Duncansville, PA USA

[5] Metroplex Clin Res Ctr, Dallas, TX USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1734

引用

页码：3613 / 3615

页数：3

共 50 条

[1] EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN, SELECTIVELY EXPANDS REGULATORY T CELLS IN PATIENTS WITH SLE: FINAL RESULTS OF A PHASE 1B MULTIPLE ASCENDING DOSE STUDY
Tchao, N.
Sarkar, N.
Hu, X.
Zhang, R.
Milmont, C.
Jin, Y. Shi
Chow, V.
Kroenke, M.
Gorski, K.
Furie, R.
Kivitz, A.
Cohen, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1343 - 1344
[2] EFAVALEUKIN ALFA IS A NOVEL IL-2 MUTEIN THAT SELECTIVELY EXPANDS REGULATORY T CELLS: PHASE 1 RESULTS AND RATIONALE FOR CLINICAL INVESTIGATION IN ULCERATIVE COLITIS
Firoozbakht, Farshid
Tchao, Nadia
Sarkar, Nandita
Gorski, Kevin
Hu, Xuguang
Rauter, Ingrid
Rossi, Claudia Pena
GASTROENTEROLOGY, 2022, 162 (07) : S977 - S977
[3] Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Sarkar, Nandita
Hu, Xuguang
Tchao, Nadia
Furie, Richard
Kivitz, Alan
Cohen, Stanley B.
Gorski, Kevin
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1957 - 1958
[4] REGULATORY T CELL DEFECTS IN SLE AND THERAPY WITH A NOVEL IL-2 MUTEIN: PHASE 1 CLINICAL RESULTS WITH EFAVALEUKIN ALFA
Sarkar, N.
Hu, X.
Tchao, N.
Furie, R.
Kivitz, A.
Cohen, S.
Gorski, K.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 92 - 93
[5] A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival.
Efe, O.
Borges, T. J.
Gassen, R. B.
Morena, L.
Al Jurdi, A.
Lape, I. T.
Bobcock, G. J.
Madsen, J. C.
Riella, L. V.
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 586 - 586
[6] A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
Peterson, Laurence B.
Bell, Charles J. M.
Howlett, Sarah K.
Pekalski, Marcin L.
Brady, Kevin
Hinton, Heather
Sauter, Denise
Todd, John A.
Umana, Pablo
Ast, Oliver
Waldhauer, Inja
Freimoser-Grundschober, Anne
Moessner, Ekkehard
Klein, Christian
Hosse, Ralf J.
Wicker, Linda S.
JOURNAL OF AUTOIMMUNITY, 2018, 95 : 1 - 14
[7] A Long-Lived IL-2 Mutein That Selectively Activates and Expands Regulatory T Cells as a Therapy for Autoimmune Disease
Issa, Fadi
TRANSPLANTATION, 2019, 103 (03) : 452 - 452
[8] LOW-DOSE IL-2 THERAPY SELECTIVELY EXPANDS REGULATORY T CELLS AND SUPPRESSES MURINE LUPUS
Humrich, J. Y.
Kloke, L.
Rose, A.
von Spee, C.
Klaus, A.
Undeutsch, R.
Riemekasten, G.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 527 - 527
[9] XmAb564, A NOVEL POTENCY-REDUCED IL-2 FC FUSION PROTEIN SELECTIVELY EXPANDS REGULATORY T CELLS: RESULTS FROM A SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT VOLUNTEERS
Clynes, R.
Key, C.
Ding, Y.
Li, L.
Woo, J.
Sadler, B.
Kanodia, J.
Sun, H.
Zitnik, R.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 275 - 275
[10] SAFETY, TOLERABILITY AND SELECTIVE EXPANSION OF REGULATORY T CELLS BY A SINGLE DOSE OF THE NOVEL IL-2 MUTEIN PT101 IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS
Sundy, J. S.
Otipoby, K. L.
Higginson-Scott, N.
Visweswaraiah, J.
Sampson, E.
Kis-Toth, K.
Monsef, A.
Petaipimol, P.
Essayan, D.
Cosenza, M. E.
Kakkar, R.
Viney, J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1167 - 1167

← 1 2 3 4 5 →